MindMed Begins Study On LSD Neutralizer Technology

MindMed (NEO: MMED) this morning announced that it has begun a study on what it refers to as “LSD neutralizer technology.” The tech is intended to stop the effects of an LSD trip while a patient is undergoing a therapy session.

The study is being conducted with the University Hospital Basel’s Liechti Lab via a phase one trial, which will evaluate the effect of ketanserin on the response to LSD after LSD administration. The project is associated with the firms LSD therapy studies referred to as Project Lucy, with the company looking to improve the therapy session with additional features to create a better patient experience.

Expected to be completed by year end, the company is effectively looking to evaluate the compound for use as an “emergency-off” switch for psychedelic assisted therapies. The tech, if successful, is ideal for when a “bad trip” occurs for the patient, or the session is not going as intended.

The study will work under the premise that the administration of 40mg of ketanserin one hour after taking LSD will significantly shorten and reduce the effects of LSD, when compared to LSD alone and a placebo. The compound is currently marketed as an antihypertensive agent.

Mindmed last traded at $5.31 on the NEO.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

MindMed Declares US$93.0 Million Net Loss, US$133.5 Million Cash Balance For 2021

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced this morning its financial...

Monday, March 28, 2022, 10:14:00 AM

Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health

In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably...

Sunday, November 1, 2020, 09:00:00 AM

MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its...

Friday, April 21, 2023, 09:41:30 AM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects...

Thursday, May 20, 2021, 08:38:23 AM